Company announcement no. 9-2018
Birkerød, 21 December 2018
ViroGates A/S (Nasdaq First North Denmark: VIRO) has published its financial calendar for 2019 with the following key dates:
20 March Deadline for submission of business to be transacted at the 2019 Annual General Meeting
27 March Annual Report 2018
25 April Annual General Meeting
29 April Interim Report Q1 2019
29 July Interim Report Q2 2019
28 October Interim Report Q3 2019
The interim and annual financial reports will be available on Virogates’ website www.virogates.com immediately after their release.
Written requests to have specific business transacted at the Annual General Meeting will be included in the agenda if received by the company no later than 20 March 2019 via email to jk@virogates.com
For further information please contact:
CEO Jakob Knudsen: Tel. (+45) 2113 1336, Email: jk@virogates.com
Certified Advisor
Västra Hamnen Corporate Finance, Per Lönn: Tel. (+46) 40 200 250, Email: per.lonn@vhcorp.se
About ViroGates
ViroGates is an international medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage test, hospital staff will get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 500 clinical trials and studies which included more than 350,000 blood samples.
Attachment